- Home
- SBFM vs INAB Comparison
SBFM vs INAB Comparison
Compare SBFM & INAB Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- SBFM
- INAB
- Stock Information
- Founded
- SBFM 2006
- INAB 2016
- Country
- SBFM United States
- INAB United States
- Employees
- SBFM N/A
- INAB N/A
- Industry
- SBFM Biotechnology: Pharmaceutical Preparations
- INAB Biotechnology: Pharmaceutical Preparations
- Sector
- SBFM Health Care
- INAB Health Care
- Exchange
- SBFM Nasdaq
- INAB Nasdaq
- Market Cap
- SBFM 6.5M
- INAB 7.5M
- IPO Year
- SBFM N/A
- INAB 2021
- Fundamental
- Price
- SBFM $1.49
- INAB $2.37
- Analyst Decision
- SBFM Strong Buy
- INAB Strong Buy
- Analyst Count
- SBFM 1
- INAB 2
- Target Price
- SBFM $15.00
- INAB $108.00
- AVG Volume (30 Days)
- SBFM 54.6K
- INAB 111.5K
- Earning Date
- SBFM 08-12-2025
- INAB 08-07-2025
- Dividend Yield
- SBFM N/A
- INAB N/A
- EPS Growth
- SBFM N/A
- INAB N/A
- EPS
- SBFM N/A
- INAB N/A
- Revenue
- SBFM $36,341,741.00
- INAB N/A
- Revenue This Year
- SBFM $32.20
- INAB N/A
- Revenue Next Year
- SBFM $32.74
- INAB N/A
- P/E Ratio
- SBFM N/A
- INAB N/A
- Revenue Growth
- SBFM 19.22
- INAB N/A
- 52 Week Low
- SBFM $1.17
- INAB $1.98
- 52 Week High
- SBFM $3.90
- INAB $21.21
- Technical
- Relative Strength Index (RSI)
- SBFM 51.16
- INAB 52.95
- Support Level
- SBFM $1.35
- INAB $2.20
- Resistance Level
- SBFM $1.52
- INAB $2.38
- Average True Range (ATR)
- SBFM 0.08
- INAB 0.13
- MACD
- SBFM 0.01
- INAB 0.04
- Stochastic Oscillator
- SBFM 66.30
- INAB 81.27
About SBFM Sunshine Biopharma Inc.
Sunshine Biopharma Inc is a pharmaceutical company offering and researching life-saving medicines in a wide variety of therapeutic areas, including oncology and antivirals. Through its subsidiaries, the company has various generic prescription drugs on the market in Canada and is also involved in developing and selling OTC supplements. In addition, the company is conducting a proprietary drug development program, which is comprised of K1.1 mRNA targeted for liver cancer and SBFM-PL4, PLpro protease inhibitor for SARS Coronavirus infections.
About INAB IN8bio Inc.
IN8bio Inc is a clinical-stage biopharmaceutical company focused on the discovery, development, and commercialization of gamma-delta T cell product candidates for solid and liquid tumors, by employing allogeneic, autologous, and genetically modified gamma-delta T cells. Its product candidates include INB-400, for the treatment of newly diagnosed glioblastoma, or GBM, INB-100 for the treatment of patients with high-risk leukemias undergoing hematopoietic stem cell transplantation, and other product candidates such as INB-200, INB-300, and INB-500.